Association between serum interleukin-6 concentrations and chronic obstructive pulmonary disease: A systematic review and meta-analysis

PeerJ

Volumn 2015, Issue 8, 2015, Pages

  Wei, Jia ^a   Xiong, Xiao Feng ^a   Lin, Yi Hua ^b   Zheng, Bi Xia ^c   Cheng, De Yun ^a  

^a SICHUAN UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

^c Third People's Hospital   (China)

Author keywords

Chronic obstructive pulmonary disease; Interleukin 6; Meta analysis; Pulmonary function; Systemic inflammation

Indexed keywords

INTERLEUKIN 6;

BIBLIOGRAPHIC DATABASE; BLOOD ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONFIDENCE INTERVAL; DISEASE CLASSIFICATION; DISEASE SEVERITY; HUMAN; INFORMATION PROCESSING; META ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SCIENTIFIC LITERATURE; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 84940367082     PISSN: None     EISSN: 21678359     Source Type: Journal    
DOI: 10.7717/peerj.1199     Document Type: Review

References (53)

1. Aaron SD, Vandemheen KL, Ramsay T, Zhang C, Avnur Z, Nikolcheva T, Quinn A. 2010. Multi analyte profiling and variability of inflammatory markers in blood and induced sputum in patients with stable COPD. Respiratory Research 11:41-52 DOI 10.1186/1465-9921-11-41.
2. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, Vestbo J, Lomas DA, Calverley PM, Wouters E, Crim C, Yates JC, Silverman EK, Coxson HO, Bakke P, Mayer RJ, Celli B. 2012. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE 7:e37483 DOI 10.1371/journal.pone.0037483.
3. Bai P, Sun Y, Jin J, Hou J, Li R, Zhang Q, Wang Y. 2011. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. Respiratory Research 12:157-164 DOI 10.1186/1465-9921-12-157.
4. Barnes PJ, Shapiro SD, Pauwels RA. 2003. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. European Respiratory Journal 22:672-688 DOI 10.1183/09031936.03.00040703.
5. Bolton CE, Broekhuizen R, Ionescu AA, Nixon LS, Wouters EF, Shale DJ, Schols AM. 2007a. Cellular protein breakdown and systemic inflammation are unaffected by pulmonary rehabilitation in COPD. Thorax 62:109-114 DOI 10.1136/thx.2006.060368.
6. Bolton CE, Evans M, Ionescu AA, Edwards SM, Morris RH, Dunseath G, Luzio SD, Owens DR, Shale DJ. 2007b. Insulin resistance and inflammation-A further systemic complication of COPD. COPD 4:121-126 DOI 10.1080/15412550701341053.
7. Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, Calverley P, Coxson H, Crim C, Edwards LD, Lomas DA, Duvoix A, MacNee W, Rennard S, Silverman E, Vestbo J, Wouters E, Agusti A. 2012. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 185:1065-1072 DOI 10.1164/rccm.201110-1792OC.
8. DeMoraes MR, Da Costa AC, Correa K de S, Junqueira-Kipnis AP, Rabahi MF. 2014. Interleukin-6 and interleukin-8 blood levels' poor association with the severity and clinical profile of ex-smokers with COPD. Journal of Chronic Obstructive Pulmonary Disease 9:735-743 DOI 10.2147/COPD.S64135.
9. Debigare R, Marquis K, Cote CH, Tremblay RR, Michaud A, LeBlanc P, Maltais F. 2003. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 124:83-89 DOI 10.1378/chest.124.1.83.
10. DerSimonian R, Laird N. 1986. Meta-analysis in clinical trials. Controlled Clinical Trials 7:177-188 DOI 10.1016/0197-2456(86)90046-2.
11. Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, MacCallum PK, Wedzicha JA. 2009. Airway and systemic inflammation and decline in lung function in patients with COPD. 2005. Chest 136:e30 DOI 10.1378/chest.09-2269.
12. Egger M, Davey SG, Schneider M, Minder C. 1997. Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634 DOI 10.1136/bmj.315.7109.629.
13. Foschino Barbaro MP, Carpagnano GE, Spanevello A, Cagnazzo MG, Barnes PJ. 2007. Inflammation, oxidative stress and systemic effects in mild chronic obstructive pulmonary disease. International Journal of Immunopathology and Pharmacology 20:753-763.
14. Gagnon P, Lemire BB, Dube A, Saey D, Porlier A, Croteau M, Provencher S, Debigare R, Maltais F. 2014. Preserved function and reduced angiogenesis potential of the quadriceps in patients with mild COPD. Respiratory Research 15:4-12 DOI 10.1186/1465-9921-15-4.
15. Gale NS, Duckers JM, Enright S, Cockcroft JR, Shale DJ, Bolton CE. 2011. Does pulmonary rehabilitation address cardiovascular risk factors in patients with COPD? BMC Pulmonary Medicine 11:20 DOI 10.1186/1471-2466-11-20.
16. GanWQ, Man SF, Senthilselvan A, Sin DD. 2004. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59:574-580 DOI 10.1136/thx.2003.019588.
17. Garcia-Rio F, Miravitlles M, Soriano JB, Munoz L, Duran-Tauleria E, Sanchez G, Sobradillo V, Ancochea J. 2010. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respiratory Research 11:63-77 DOI 10.1186/1465-9921-11-63.
18. Hacker S, Lambers C, Hoetzenecker K, Pollreisz A, Aigner C, Lichtenauer M, Mangold A, Niederpold T, Zimmermann M, Taghavi S, Klepetko W, Ankersmit HJ. 2009. Elevated HSP27, HSP70 and HSP90 alpha in chronic obstructive pulmonary disease: markers for immune activation and tissue destruction. Clinical Lab 55:31-40.
19. Hageman GJ, Larik I, Pennings HJ, Haenen GR, Wouters EF, Bast A. 2003. Systemic poly (ADP-ribose) polymerase-1 activation, chronic inflammation, and oxidative stress in COPD patients. Free Radical Biology and Medicine 35:140-148 DOI 10.1016/S0891-5849(03)00237-5.
20. He Z, Chen Y, Chen P, Wu G, Cai S. 2010. Local inflammation occurs before systemic inflammation in patients with COPD. Respirology 15:478-484 DOI 10.1111/j.1440-1843.2010.01709.x.
21. Heinrich PC, Castell JV, Andus T. 1990. Interleukin-6 and the acute phase response. Biochemical Journal 265:621-636 DOI 10.1042/bj2650621.
22. Higashimoto Y, Yamagata Y, Taya S, Iwata T, Okada M, Ishiguchi T, Sato H, Itoh H. 2008. Systemic inflammation in chronic obstructive pulmonary disease and asthma: similarities and differences. Respirology 13:128-133 DOI 10.1111/j.1440-1843.2007.01170.x.
23. Higgins JP, Thompson SG. 2002. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 21:1539-1558 DOI 10.1002/sim.1186.
24. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD. 2004. The nature of small-airway obstruction in chronic obstructive pulmonary disease. New England Journal of Medicine 350:2645-2653 DOI 10.1056/NEJMoa032158.
25. Huertas A, Testa U, Riccioni R, Petrucci E, Riti V, Savi D, Serra P, Bonsignore MR, Palange P. 2010. Bone marrow-derived progenitors are greatly reduced in patients with severe COPD and low-BMI. Respiration Physiology & Neurobiology 170:23-31 DOI 10.1016/j.resp.2009.10.003.
26. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA. 2006. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 173:71-78 DOI 10.1164/rccm.200505-704OC.
27. Itoh T, Nagaya N, Yoshikawa M, Fukuoka A, Takenaka H, Shimizu Y, Haruta Y, Oya H, Yamagishi M, Hosoda H, Kangawa K, Kimura H. 2004. Elevated plasma ghrelin level in underweight patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 170:879-882 DOI 10.1164/rccm.200310-1404OC.
28. Jammes Y, Steinberg JG, Ba A, Delliaux S, Bregeon F. 2008. Enhanced exercise-induced plasma cytokine response and oxidative stress in COPD patients depend on blood oxygenation. Clinical Physiology and Functional Imaging 28:182-188 DOI 10.1111/j.1475-097X.2008.00795.x.
29. Johnson PM, Vogt SK, Burney MW, Muglia LJ. 2002. COX-2 inhibition attenuates anorexia during systemic inflammation without impairing cytokine production. American Journal of Physiology, Endocrinology and Metabolism 282:E650-E656 DOI 10.1152/ajpendo.00388.2001.
30. Ju CR, Chen RC. 2012. Serum myostatin levels and skeletal muscle wasting in chronic obstructive pulmonary disease. Respiratory Medicine 106:102-108 DOI 10.1016/j.rmed.2011.07.016.
31. Karadag F, Karul AB, Cildag O, Yilmaz M, Ozcan H. 2008a. Biomarkers of systemic inflammation in stable and exacerbation phases of COPD. Lung 186:403-409 DOI 10.1007/s00408-008-9106-6.
32. Karadag F, Kirdar S, Karul AB, Ceylan E. 2008b. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. European Journal of Internal Medicine 19:104-108 DOI 10.1016/j.ejim.2007.04.026.
33. Koechlin C, Couillard A, Cristol JP, Chanez P, Hayot M, Le GD, Prefaut C. 2004. Does systemic inflammation trigger local exercise-induced oxidative stress in COPD? European Respiratory Journal 23:538-544 DOI 10.1183/09031936.04.00069004.
34. Kotler DP. 2000. Cachexia. Annals of Internal Medicine 133:622-634 DOI 10.7326/0003-4819-133-8-200010170-00015.
35. Oncel C, Baser S, Cam M, Akdag B, Taspinar B, Evyapan F. 2010. Peripheral neuropathy in chronic obstructive pulmonary disease. COPD 7:11-16 DOI 10.3109/15412550903499480.
36. Palange P, Testa U, Huertas A, Calabro L, Antonucci R, Petrucci E, Pelosi E, Pasquini L, Satta A, Morici G, Vignola MA, Bonsignore MR. 2006. Circulating haemopoietic and endothelial progenitor cells are decreased in COPD. European Respiratory Journal 27:529-541 DOI 10.1183/09031936.06.00120604.
37. Rabinovich RA, Figueras M, Ardite E, Carbo N, Troosters T, Filella X, Barbera JA, Fernandez-Checa JC, Argiles JM, Roca J. 2003. Increased tumour necrosis factor-alpha plasma levels during moderate-intensity exercise in COPD patients. European Respiratory Journal 21:789-794 DOI 10.1183/09031936.03.00042702.
38. Rosenberg SR, Kalhan R. 2012. Biomarkers in chronic obstructive pulmonary disease. Translational Research 159:228-237 DOI 10.1016/j.trsl.2012.01.019.
39. Ross R. 1999. Atherosclerosis is an inflammatory disease. American Heart Journal 138:S419-S420 DOI 10.1016/S0002-8703(99)70266-8.
40. Sabit R, Bolton CE, Edwards PH, Pettit RJ, Evans WD, McEniery CM, Wilkinson IB, Cockcroft JR, Shale DJ. 2007. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 175:1259-1265 DOI 10.1164/rccm.200701-067OC.
41. Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R, Muller C, Struck J, Muller B, Tamm M. 2007. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 131:1058-1067 DOI 10.1378/chest.06-2336.
42. Tanni SE, Pelegrino NR, Angeleli AY, Correa C, Godoy I. 2010. Smoking status and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients. Journal of Inflammation 7:29-35 DOI 10.1186/1476-9255-7-29.
43. Tomoda K, Yoshikawa M, Itoh T, Tamaki S, Fukuoka A, Komeda K, Kimura H. 2007. Elevated circulating plasma adiponectin in underweight patients with COPD. Chest 132:135-140 DOI 10.1378/chest.07-0227.
44. Uzum AK, Aydin MM, Tutuncu Y, Omer B, Kiyan E, Alagol F. 2014. Serum ghrelin and adiponectin levels are increased but serum leptin level is unchanged in low weight chronic obstructive pulmonary disease patients. European Journal of Internal Medicine 25:364-369 DOI 10.1016/j.ejim.2013.02.012.
45. Van Helvoort HA, Heijdra YF, Thijs HM, Vina J, Wanten GJ, Dekhuijzen PN. 2006. Exercise-induced systemic effects in muscle-wasted patients with COPD. Medicine and Science in Sports and Exercise 38:1543-1552 DOI 10.1249/01.mss.0000228331.13123.53.
46. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. 2013. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. American Journal of Respiratory and Critical Care Medicine 187:347-365 DOI 10.1164/rccm.201204-0596PP.
47. Vogiatzis I, Stratakos G, Simoes DC, Terzis G, Georgiadou O, Roussos C, Zakynthinos S. 2007. Effects of rehabilitative exercise on peripheral muscle TNFalpha, IL-6, IGF-I and MyoD expression in patients with COPD. Thorax 62:950-956 DOI 10.1136/thx.2006.069310.
48. Walston JD, Fallin MD, Cushman M, Lange L, Psaty B, Jenny N, Browner W, Tracy R, Durda P, Reiner A. 2007. IL-6 gene variation is associated with IL-6 and C-reactive protein levels but not cardiovascular outcomes in the cardiovascular health study. Human Genetics 122:485-494 DOI 10.1007/s00439-007-0428-x.
49. Walter RE, Wilk JB, Larson MG, Vasan RS, Keaney Jr JF, Lipinska I, O'Connor GT, Benjamin EJ. 2008. Systemic inflammation and COPD: the Framingham heart study. Chest 133:19-25 DOI 10.1378/chest.07-0058.
50. Wang XR, Li YP, Gao S, Xia W, Gao K, Kong QH, Qi H, Wu L, Zhang J, Qu JM, Bai CX. 2014. Increased serum levels of lipocalin-1 and-2 in patients with stable chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 9:543-549 DOI 10.2147/COPD.S62700.
51. Yasuda N, Gotoh K, Minatoguchi S, Asano K, Nishigaki K, Nomura M, Ohno A, Watanabe M, Sano H, Kumada H, Sawa T, Fujiwara H. 1998. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Respiratory Medicine 92:993-999 DOI 10.1016/S0954-6111(98)90343-2.
52. Yende S, Waterer GW, Tolley EA, Newman AB, Bauer DC, Taaffe DR, Jensen R, Crapo R, Rubin S, Nevitt M, Simonsick EM, Satterfield S, Harris T, Kritchevsky SB. 2006. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 61:10-16 DOI 10.1136/thx.2004.034181.
53. Ying BW, Song XB, Fan H, Wang LL, Li YS, Cheng Z, Cheng H, Wen FQ. 2008. Plasma ghrelin levels and weight loss in Chinese Uygur patients with chronic obstructive pulmonary disease. Journal of International Medical Research 36:1371-1377 DOI 10.1177/147323000803600626.